IP Library › Granted Patent US 9,622,968
Granted Patent B2
US 9,622,968 · App. 14/534,847 · Granted Apr 18, 2017

Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

Inventor: Cuthbert O. Simpkins (Shreveport, LA)
Assignee: VIVACELLE BIO, INC.
A61K9/107A23L29/10A23L33/115A23L33/175A61K8/0291A61K9/0019A61K9/50A61K31/4172A61K31/66A61K45/06A61K47/00A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,622,968
App. No.
14/534,847
Granted
Apr 18, 2017
Kind
B2
Abstract

A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.

Claims (41)

1. A blood volume expander, comprising:

an amphiphilic emulsifier;

a polar liquid carrier; and

a buffering agent of histidine or a histidine-containing peptide at a final concentration of 0.1 mM to 30 mM,

wherein said amphiphilic emulsifier forms free-moving micelles having a lipophilic core in said polar liquid carrier and wherein said blood volume expander is free of hemoglobin and fluorocarbon.

2. The blood volume expander of claim 1 , wherein said micelles have an average diameter in the range of 3-300 nm.

3. The blood volume expander of claim 2 , wherein said micelles have an average diameter in the range of 30-100 nm.

4. The blood volume expander of claim 2 , wherein said micelles have an average diameter in the range of 90-100 nm.

5. The blood volume expander of claim 2 , wherein said micelles have an average diameter of about 100 nm.

6. The blood volume expander of claim 1 , wherein said blood expander further comprises a lipid component and wherein said lipid component comprises soybean oil or an oil rich in omega 3 fatty acid in an amount of 10-70% (w/v) of said blood volume expander.

7. The blood volume expander of claim 6 , wherein said lipid component comprises soybean oil or an oil rich in omega 3 fatty acid in an amount of 20-30% (w/v) of said blood volume expander.

8. The blood volume expander of claim 6 , wherein said oil rich in omega 3 fatty acid is selected from the group consisting of chia bean oil, algae oil, pumpkin oil, flaxseed oil and fish oil.

9. The blood volume expander of claim 1 , wherein said amphiphilic emulsifier constitutes about 0.5-50% (w/v) of said blood volume expander.

10. The blood volume expander of claim 9 , wherein said amphiphilic emulsifier constitutes about 2-30% (w/v) of said blood volume expander.

11. The blood volume expander of claim 10 , wherein said amphiphilic emulsifier constitutes about 5-20% (w/v) of said blood volume expander.

12. The blood volume expander of claim 11 , wherein said amphiphilic emulsifier constitutes about 10-15% (w/v) of said blood volume expander.

13. The blood volume expander of claim 1 , wherein said amphiphilic emulsifier comprises egg phospholipids.

14. The blood volume expander of claim 1 , wherein said blood volume expander comprises histidine at a final of concentration of 1-10 mM.

15. The blood volume expander of claim 1 , wherein said blood volume expander further comprises glycerol or mannitol in an amount of 2-15% (w/v) of said blood volume expander.

16. The blood volume expander of claim 1 , further comprising β-endorphin at a final concentration of 0.01-100 nM.

17. The blood volume expander of claim 1 , wherein said micelles have an average diameter of 90-120 nm.

18. The blood volume expander of claim 1 , further comprising one or more coagulation enhancers.

19. The blood volume expander of claim 1 , further comprising one or more oncotic agents.

20. The blood volume expander of claim 1 , further comprising one or more immunomodulatory agents.

21. The blood volume expander of claim 1 , further comprising one or more anti-inflammatory agents.

22. The blood volume expander of claim 1 , further comprising one or more additives selected from the group consisting of antioxidants, antibiotics, anti-fungal agents, vitamins, amino acids, vessel expanders, surfactants, antibodies and mediators of vascular potency.

23. A blood volume expander, comprising:

an amphiphilic emulsifier;

a polar liquid carrier; and

a buffering agent of histidine or a histidine-containing peptide at a final concentration of 0.1 mM; to 30 mM;

wherein said amphiphilic emulsifier forms free-moving micelles or liposomes in said polar liquid carrier, and wherein said blood volume expander is free of hemoglobin and fluorocarbon.

24. The blood volume expander of claim 23 , wherein said blood volume expander further comprises a lipid component.

25. The blood volume expander of claim 23 , further comprising β-endorphin at a final concentration of 0.01 nM to 100 nM.

26. The blood volume expander of claim 23 , comprising 0.1 fM -10 mM cysteine, or an oligopeptide containing glycylglycine.

27. The blood volume expander of claim 23 , comprising 3-30 mM histidine.

28. The blood volume expander of claim 23 , wherein said micelles or liposomes have an average diameter of 90-120 nm.

29. The blood volume expander of claim 23 , wherein said micelles or liposomes have an average diameter of 90-100 nm.

30. The blood volume expander of claim 23 , wherein said micelles or liposomes have an average diameter of 100-110 nm.

31. The blood volume expander of claim 23 , wherein said micelles or liposomes have an average diameter of 110-120 nm.

32. The blood volume expander of claim 23 , further comprising one or more additives selected from the group consisting of coagulation enhancers, oncotic agents, immunomodulatory agents, and anti-inflammatory agents.

33. The pharmaceutical composition of claim 23 , further comprising one or more additives selected from the group consisting of antioxidants; antibiotics; anti-fungal agents; vitamins; amino acids; vessel expanders; surfactants; antibodies and mediators of vascular potency.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: SIMPKINS, CUTHBERT O.
To: VIVACELLE BIO, INC.
Reel/Frame 035588/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2015
From: SIMPKINS, CUTHBERT O
To: VIVACELLE BIO, INC.
Reel/Frame 035112/0457 →
Continuity (12)
Continuation 13963521 · Aug 9, 2013
Continuation In Part 13273471 · Oct 14, 2011
Continuation In Part 12314737 · Dec 16, 2008
Continuation In Part 13963521
Continuation In Part 12696107 · Jan 29, 2010
Provisional Application 61016443 · Dec 22, 2007
Provisional Application 61064639 · Mar 18, 2008
Provisional Application 61202124 · Jan 30, 2009
Provisional Application 61681930 · Aug 10, 2012
Provisional Application 61432919 · Jan 14, 2011
Provisional Application 61490816 · May 27, 2011
Related Publication 20150064259A1 · Mar 5, 2015